CN109666070A - 单克隆抗体mers-4v2及其编码基因和应用 - Google Patents
单克隆抗体mers-4v2及其编码基因和应用 Download PDFInfo
- Publication number
- CN109666070A CN109666070A CN201710951002.2A CN201710951002A CN109666070A CN 109666070 A CN109666070 A CN 109666070A CN 201710951002 A CN201710951002 A CN 201710951002A CN 109666070 A CN109666070 A CN 109666070A
- Authority
- CN
- China
- Prior art keywords
- sequence
- ser
- val
- amino acids
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 44
- 208000025370 Middle East respiratory syndrome Diseases 0.000 title abstract description 50
- 150000001413 amino acids Chemical group 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000029058 respiratory gaseous exchange Effects 0.000 claims abstract description 15
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 15
- 241000711573 Coronaviridae Species 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000470 constituent Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 abstract description 30
- 229960005486 vaccine Drugs 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 44
- 239000007788 liquid Substances 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 241000700605 Viruses Species 0.000 description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000035772 mutation Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 241000238631 Hexapoda Species 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241001112090 Pseudovirus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 4
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 4
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 4
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 4
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 4
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 4
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 4
- 108010047857 aspartylglycine Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 108010031719 prolyl-serine Proteins 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 3
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 3
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 3
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 3
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 3
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 3
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 3
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- MHQXIBRPDKXDGZ-ZFWWWQNUSA-N Met-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@@H](N)CCSC)C(O)=O)=CNC2=C1 MHQXIBRPDKXDGZ-ZFWWWQNUSA-N 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 102000029301 Protein S Human genes 0.000 description 3
- 108010066124 Protein S Proteins 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- INCNPLPRPOYTJI-JBDRJPRFSA-N Ser-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N INCNPLPRPOYTJI-JBDRJPRFSA-N 0.000 description 3
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 3
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 3
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 3
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 3
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108010020532 tyrosyl-proline Proteins 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 2
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 2
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 2
- FVNAUOZKIPAYNA-BPNCWPANSA-N Ala-Met-Tyr Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FVNAUOZKIPAYNA-BPNCWPANSA-N 0.000 description 2
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 2
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 2
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 2
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 2
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 2
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 2
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 2
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 2
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 2
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 2
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 2
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 2
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 2
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 2
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 2
- YMBAVNPKBWHDAW-CIUDSAMLSA-N Cys-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N YMBAVNPKBWHDAW-CIUDSAMLSA-N 0.000 description 2
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 2
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 2
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 2
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 2
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 2
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 2
- BPCLDCNZBUYGOD-BPUTZDHNSA-N Glu-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 BPCLDCNZBUYGOD-BPUTZDHNSA-N 0.000 description 2
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 2
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 2
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 2
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 2
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 2
- QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 2
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 2
- FYVHHKMHFPMBBG-GUBZILKMSA-N His-Gln-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FYVHHKMHFPMBBG-GUBZILKMSA-N 0.000 description 2
- TTYKEFZRLKQTHH-MELADBBJSA-N His-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O TTYKEFZRLKQTHH-MELADBBJSA-N 0.000 description 2
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 2
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 2
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 2
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 2
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 2
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 2
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 2
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 2
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 2
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 2
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 2
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 2
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 2
- RKIIYGUHIQJCBW-SRVKXCTJSA-N Met-His-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RKIIYGUHIQJCBW-SRVKXCTJSA-N 0.000 description 2
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 2
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 2
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 2
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 2
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 2
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 2
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 2
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 2
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 2
- MHHQQZIFLWFZGR-DCAQKATOSA-N Pro-Lys-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O MHHQQZIFLWFZGR-DCAQKATOSA-N 0.000 description 2
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 2
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 2
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 2
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 2
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 2
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 2
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 2
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 2
- ICHZYBVODUVUKN-SRVKXCTJSA-N Ser-Asn-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ICHZYBVODUVUKN-SRVKXCTJSA-N 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- RRVFEDGUXSYWOW-BZSNNMDCSA-N Ser-Phe-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RRVFEDGUXSYWOW-BZSNNMDCSA-N 0.000 description 2
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 2
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 2
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 2
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 2
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 2
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 2
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 2
- KGKWKSSSQGGYAU-SUSMZKCASA-N Thr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KGKWKSSSQGGYAU-SUSMZKCASA-N 0.000 description 2
- SXAGUVRFGJSFKC-ZEILLAHLSA-N Thr-His-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SXAGUVRFGJSFKC-ZEILLAHLSA-N 0.000 description 2
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 2
- IHAPJUHCZXBPHR-WZLNRYEVSA-N Thr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N IHAPJUHCZXBPHR-WZLNRYEVSA-N 0.000 description 2
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 2
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 2
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 2
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 description 2
- XGFGVFMXDXALEV-XIRDDKMYSA-N Trp-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N XGFGVFMXDXALEV-XIRDDKMYSA-N 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 2
- NLMXVDDEQFKQQU-CFMVVWHZSA-N Tyr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLMXVDDEQFKQQU-CFMVVWHZSA-N 0.000 description 2
- JJNXZIPLIXIGBX-HJPIBITLSA-N Tyr-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JJNXZIPLIXIGBX-HJPIBITLSA-N 0.000 description 2
- GZUIDWDVMWZSMI-KKUMJFAQSA-N Tyr-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GZUIDWDVMWZSMI-KKUMJFAQSA-N 0.000 description 2
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 2
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 2
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 2
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 2
- HQYVQDRYODWONX-DCAQKATOSA-N Val-His-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N HQYVQDRYODWONX-DCAQKATOSA-N 0.000 description 2
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 2
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 2
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 2
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 2
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 2
- SDHZOOIGIUEPDY-JYJNAYRXSA-N Val-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 SDHZOOIGIUEPDY-JYJNAYRXSA-N 0.000 description 2
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 2
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 2
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 2
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 2
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 2
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
- 108010091871 leucylmethionine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 2
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 2
- 108010038745 tryptophylglycine Proteins 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- LGQPPBQRUBVTIF-JBDRJPRFSA-N Ala-Ala-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LGQPPBQRUBVTIF-JBDRJPRFSA-N 0.000 description 1
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 1
- GFBLJMHGHAXGNY-ZLUOBGJFSA-N Ala-Asn-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O GFBLJMHGHAXGNY-ZLUOBGJFSA-N 0.000 description 1
- ZEXDYVGDZJBRMO-ACZMJKKPSA-N Ala-Asn-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N ZEXDYVGDZJBRMO-ACZMJKKPSA-N 0.000 description 1
- YSMPVONNIWLJML-FXQIFTODSA-N Ala-Asp-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O YSMPVONNIWLJML-FXQIFTODSA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- GFEDXKNBZMPEDM-KZVJFYERSA-N Ala-Met-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFEDXKNBZMPEDM-KZVJFYERSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 1
- PHQXWZGXKAFWAZ-ZLIFDBKOSA-N Ala-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 PHQXWZGXKAFWAZ-ZLIFDBKOSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 1
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 1
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 1
- CUQUEHYSSFETRD-ACZMJKKPSA-N Asn-Asp-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N CUQUEHYSSFETRD-ACZMJKKPSA-N 0.000 description 1
- JZRLLSOWDYUKOK-SRVKXCTJSA-N Asn-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N JZRLLSOWDYUKOK-SRVKXCTJSA-N 0.000 description 1
- HLTLEIXYIJDFOY-ZLUOBGJFSA-N Asn-Cys-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O HLTLEIXYIJDFOY-ZLUOBGJFSA-N 0.000 description 1
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 1
- FODVBOKTYKYRFJ-CIUDSAMLSA-N Asn-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N FODVBOKTYKYRFJ-CIUDSAMLSA-N 0.000 description 1
- NTWOPSIUJBMNRI-KKUMJFAQSA-N Asn-Lys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTWOPSIUJBMNRI-KKUMJFAQSA-N 0.000 description 1
- NONWUQAWAANERO-BZSNNMDCSA-N Asp-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 NONWUQAWAANERO-BZSNNMDCSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- IIGHQOPGMGKDMT-SRVKXCTJSA-N Cys-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N IIGHQOPGMGKDMT-SRVKXCTJSA-N 0.000 description 1
- VPQZSNQICFCCSO-BJDJZHNGSA-N Cys-Leu-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VPQZSNQICFCCSO-BJDJZHNGSA-N 0.000 description 1
- VRJZMZGGAKVSIQ-SRVKXCTJSA-N Cys-Tyr-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VRJZMZGGAKVSIQ-SRVKXCTJSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 1
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 1
- BJPPYOMRAVLXBY-YUMQZZPRSA-N Gln-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N BJPPYOMRAVLXBY-YUMQZZPRSA-N 0.000 description 1
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 1
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 1
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 1
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- OXEMJGCAJFFREE-FXQIFTODSA-N Glu-Gln-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O OXEMJGCAJFFREE-FXQIFTODSA-N 0.000 description 1
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 1
- CAQXJMUDOLSBPF-SUSMZKCASA-N Glu-Thr-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAQXJMUDOLSBPF-SUSMZKCASA-N 0.000 description 1
- CIMULJZTTOBOPN-WHFBIAKZSA-N Gly-Asn-Asn Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CIMULJZTTOBOPN-WHFBIAKZSA-N 0.000 description 1
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 1
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 1
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- SFOXOSKVTLDEDM-HOTGVXAUSA-N Gly-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CN)=CNC2=C1 SFOXOSKVTLDEDM-HOTGVXAUSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- IDNNYVGVSZMQTK-IHRRRGAJSA-N His-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N IDNNYVGVSZMQTK-IHRRRGAJSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 1
- JNLSTRPWUXOORL-MMWGEVLESA-N Ile-Ser-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N JNLSTRPWUXOORL-MMWGEVLESA-N 0.000 description 1
- JERJIYYCOGBAIJ-OBAATPRFSA-N Ile-Tyr-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JERJIYYCOGBAIJ-OBAATPRFSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 1
- LAGPXKYZCCTSGQ-JYJNAYRXSA-N Leu-Glu-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LAGPXKYZCCTSGQ-JYJNAYRXSA-N 0.000 description 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 description 1
- FIYMBBHGYNQFOP-IUCAKERBSA-N Leu-Gly-Gln Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N FIYMBBHGYNQFOP-IUCAKERBSA-N 0.000 description 1
- KUIDCYNIEJBZBU-AJNGGQMLSA-N Leu-Ile-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O KUIDCYNIEJBZBU-AJNGGQMLSA-N 0.000 description 1
- ONPJGOIVICHWBW-BZSNNMDCSA-N Leu-Lys-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ONPJGOIVICHWBW-BZSNNMDCSA-N 0.000 description 1
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 1
- GOFJOGXGMPHOGL-DCAQKATOSA-N Leu-Ser-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(C)C GOFJOGXGMPHOGL-DCAQKATOSA-N 0.000 description 1
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
- RZHLIPMZXOEJTL-AVGNSLFASA-N Lys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N RZHLIPMZXOEJTL-AVGNSLFASA-N 0.000 description 1
- NNCDAORZCMPZPX-GUBZILKMSA-N Lys-Gln-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N NNCDAORZCMPZPX-GUBZILKMSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- MGKFCQFVPKOWOL-CIUDSAMLSA-N Lys-Ser-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N MGKFCQFVPKOWOL-CIUDSAMLSA-N 0.000 description 1
- LKDXINHHSWFFJC-SRVKXCTJSA-N Lys-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N LKDXINHHSWFFJC-SRVKXCTJSA-N 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001116436 Mus musculus Xaa-Pro dipeptidase Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- DMEYUTSDVRCWRS-ULQDDVLXSA-N Phe-Lys-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DMEYUTSDVRCWRS-ULQDDVLXSA-N 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- VDGTVWFMRXVQCT-GUBZILKMSA-N Pro-Glu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 VDGTVWFMRXVQCT-GUBZILKMSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- FDINZVJXLPILKV-DCAQKATOSA-N Pro-His-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O FDINZVJXLPILKV-DCAQKATOSA-N 0.000 description 1
- UREQLMJCKFLLHM-NAKRPEOUSA-N Pro-Ile-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UREQLMJCKFLLHM-NAKRPEOUSA-N 0.000 description 1
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 1
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 1
- MDAWMJUZHBQTBO-XGEHTFHBSA-N Pro-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1)O MDAWMJUZHBQTBO-XGEHTFHBSA-N 0.000 description 1
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 1
- IIRBTQHFVNGPMQ-AVGNSLFASA-N Pro-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 IIRBTQHFVNGPMQ-AVGNSLFASA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 description 1
- TUYBIWUZWJUZDD-ACZMJKKPSA-N Ser-Cys-Gln Chemical compound OC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCC(N)=O TUYBIWUZWJUZDD-ACZMJKKPSA-N 0.000 description 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- HEUVHBXOVZONPU-BJDJZHNGSA-N Ser-Leu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HEUVHBXOVZONPU-BJDJZHNGSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- XQAPEISNMXNKGE-FXQIFTODSA-N Ser-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CS)C(=O)O XQAPEISNMXNKGE-FXQIFTODSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 1
- STIAINRLUUKYKM-WFBYXXMGSA-N Ser-Trp-Ala Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 STIAINRLUUKYKM-WFBYXXMGSA-N 0.000 description 1
- UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 1
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 1
- MMTOHPRBJKEZHT-BWBBJGPYSA-N Thr-Cys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O MMTOHPRBJKEZHT-BWBBJGPYSA-N 0.000 description 1
- UUSQVWOVUYMLJA-PPCPHDFISA-N Thr-Lys-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UUSQVWOVUYMLJA-PPCPHDFISA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- WFAUDCSNCWJJAA-KXNHARMFSA-N Thr-Lys-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(O)=O WFAUDCSNCWJJAA-KXNHARMFSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- BTAJAOWZCWOHBU-HSHDSVGOSA-N Thr-Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)C(C)C)C(O)=O)=CNC2=C1 BTAJAOWZCWOHBU-HSHDSVGOSA-N 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 1
- BYAKMYBZADCNMN-JYJNAYRXSA-N Tyr-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYAKMYBZADCNMN-JYJNAYRXSA-N 0.000 description 1
- GPLTZEMVOCZVAV-UFYCRDLUSA-N Tyr-Tyr-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 GPLTZEMVOCZVAV-UFYCRDLUSA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- YKBUNNNRNZZUID-UFYCRDLUSA-N Tyr-Val-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YKBUNNNRNZZUID-UFYCRDLUSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 1
- DLYOEFGPYTZVSP-AEJSXWLSSA-N Val-Cys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N DLYOEFGPYTZVSP-AEJSXWLSSA-N 0.000 description 1
- AAOPYWQQBXHINJ-DZKIICNBSA-N Val-Gln-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N AAOPYWQQBXHINJ-DZKIICNBSA-N 0.000 description 1
- ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 1
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 1
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 1
- GQMNEJMFMCJJTD-NHCYSSNCSA-N Val-Pro-Gln Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O GQMNEJMFMCJJTD-NHCYSSNCSA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- MIAZWUMFUURQNP-YDHLFZDLSA-N Val-Tyr-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N MIAZWUMFUURQNP-YDHLFZDLSA-N 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种单克隆抗体MERS‑4V2及其编码基因和应用。本发明提供了单克隆抗体MERS‑4V2,是一种IgG抗体,由重链和轻链组成;所述重链中的重链可变区中的CDR1、CDR2和CDR3依次为序列表的序列1自N末端第45‑52位氨基酸残基、第70‑77位氨基酸残基和第116‑120位氨基酸残基;所述轻链中的轻链可变区中的CDR1、CDR2和CDR3依次为序列表的序列3自N末端第45‑52位氨基酸残基、第70‑72位氨基酸残基和第109‑119位氨基酸残基。本发明还保护所述IgG抗体在制备用于抑制中东呼吸综合征冠状病毒的药物中的应用。本发明对于治疗和/或预防新型冠状病毒MERS‑CoV的药物(疫苗)的开发具有广泛的应用前景。
Description
技术领域
本发明涉及一种单克隆抗体MERS-4V2及其编码基因和应用。
背景技术
中东呼吸综合征是由一种新型冠状病毒-中东呼吸综合征冠状病毒(MERS-CoV)引起的病毒性呼吸道疾病。新型冠状病毒MERS-CoV于2012年首次在中东地区被发现感染人类,随后这种病毒感染疾病又先后出现在欧洲几个国家和地区。超过半数的感染病人均会出现严重的呼吸道疾病,其临床症状同2003年爆发的由SARS-CoV引起的疾病非常相似。由于这种疾病可以人传染给人,因此引起了全世界的高度关注。到目前为止,还没有特异性的药物和疫苗对这种疾病进行治疗和预防。
MERS-CoV利用其表面的膜蛋白S进入易感细胞。S蛋白由位于N端的S1结构域和位于近膜端的S2结构域和跨膜结构域组成,其中病毒对细胞易感性是由S1结构域决定的。通过利用MERS-CoV S1结构域进行共纯化实验,在2013年初Raj的研究小组确定了dipeptideyl peptidase 4(DPP4,也称为CD26)为MERS-CoV的受体。
发明内容
本发明的目的是提供一种单克隆抗体MERS-4V2及其编码基因和应用。
本发明提供了单克隆抗体MERS-4V2,是一种IgG抗体,由重链和轻链组成;所述重链中的重链可变区中的CDR1、CDR2和CDR3依次为序列表的序列1自N末端第45-52位氨基酸残基、第70-77位氨基酸残基和第116-120位氨基酸残基;所述轻链中的轻链可变区中的CDR1、CDR2和CDR3依次为序列表的序列3自N末端第45-52位氨基酸残基、第70-72位氨基酸残基和第109-119位氨基酸残基。
所述重链中的重链可变区为如下(a1)或(a2):(a1)序列表的序列1自N末端第17-131位氨基酸残基组成的蛋白质;(a2)序列表的序列1自N末端第1-131位氨基酸残基组成的蛋白质。
所述轻链中的轻链可变区为如下(b1)或(b2):(b1)序列表的序列3自N末端第17-129位氨基酸残基组成的蛋白质;(b2)序列表的序列3自N末端第1-129位氨基酸残基组成的蛋白质。
所述重链为如下(c1)或(c2):(c1)序列表的序列1自N末端第17-461位氨基酸残基组成的蛋白质;(c2)序列表的序列3所示的蛋白质。
所述轻链为如下(d1)或(d2):(d1)序列表的序列3自N末端第17-235位氨基酸残基组成的蛋白质;(d2)序列表的序列3所示的蛋白质。
本发明还保护编码所述IgG抗体的基因,其特征在于:
编码所述重链的基因为如下(1)或(2):
(1)序列表的序列2自5’末端第49-1383位核苷酸所示的DNA分子;
(2)序列表的序列2所示的DNA分子;
编码所述轻链的基因为如下(3)或(4):
(3)序列表的序列4自5’末端第49-705位核苷酸所示的DNA分子;
(4)序列表的序列4所示的DNA分子。
本发明还保护所述IgG抗体在制备用于抑制中东呼吸综合征冠状病毒的药物中的应用。本发明还保护一种用于抑制中东呼吸综合征冠状病毒的药物,其活性成分为所述IgG抗体。
本发明还保护所述IgG抗体在制备用于中和中东呼吸综合征冠状病毒的药物中的应用。本发明还保护一种用于中和中东呼吸综合征冠状病毒的药物,其活性成分为所述IgG抗体。
本发明还保护所述IgG抗体在制备用于预防和/或治疗中东呼吸综合征的药物中的应用。本发明还保护一种用于预防和/或治疗中东呼吸综合征的药物,其活性成分为所述IgG抗体。
本发明对于治疗和/或预防新型冠状病毒MERS-CoV的药物(疫苗)的开发具有广泛的应用前景。
附图说明
图1为实施例2中的SDS-PAGE电泳图。
图2为实施例3中的结合活性结果。
具体实施方式
以下的实施例便于更好地理解本发明,但并不限定本发明。下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的试验材料,如无特殊说明,均为自常规生化试剂商店购买得到的。以下实施例中的定量试验,均设置三次重复实验,结果取平均值。如无特殊说明,实施例中所用的PBS缓冲液均为pH7.2、0.01mM的PBS缓冲液。TCID50,Tissue culture infective dose 50%,半数组织培养感染剂量。
pMD18-T载体:宝生物工程(大连)有限公司,产品目录号为D101A。pFastBacTMdual载体(pFastBacTMdual vector):Invitrogen公司,产品目录号为10359-016。pcDNA3.1(+)载体:Invitrogen公司。293T细胞:美国模式培养物集存库(American type culturecollection,ATCC),产品目录号为CRL-3216TM。Sf9细胞:Invitrogen公司,产品目录号为11496-015。Huh7细胞:中国科学院细胞库,产品目录号为TCHu18。大肠杆菌DH10Bac:Invitrogen公司,产品目录号为10359-016。昆虫细胞培养基:Lonza公司,产品目录号为12-730Q。
骨架质粒pNL4-3R-E-luciferase:参考文献:He J,Choe S,Walker R,DiMarzioP,Morgan DO,Landau NR.J Virol 69:6705–6711,1995.。
实施例1、单克隆抗体MERS-4V2的发现
一、单克隆抗体MERS-4的发现
通过序列和模型分析发现MERS-CoV可能有一个潜在的受体结合域(ReceptorBinding Domain,RBD),将RBD和可溶性DPP4蛋白共结晶,解析蛋白的结构,找到了RBD与DPP4结合的关键氨基酸位点。利用纯化的RBD进行动物免疫,发现其具有较强的诱导中和抗体产生的能力。利用RBD筛选展示在酵母表面的人类非免疫scFvs文库(scFvs的英文全称为“single-chain variable fragments”),得到了若干具有中和活性的单克隆抗体。将其中一个单克隆抗体命名为单克隆抗体MERS-4(属于IgG1抗体)。
单克隆抗体MERS-4的重链如序列表的序列5所示,轻链如序列表的序列3所示。
单克隆抗体MERS-4能够特异结合MERS-CoV膜蛋白S的RBD,对MERS-CoV的假型病毒具有中和活性。但是,单克隆抗体MERS-4存在表达量低的问题,很难大批量生产,因此将其作为治疗性抗体药物用于临床存在很大的局限性。
二、单克隆抗体MERS-4V2的发现
对单克隆抗体MERS-4进行改造,经过大量分析、筛选、构建定点随机突变文库以及效果验证,获得一个新的单克隆抗体,将其命名为单克隆抗体MERS-4V2。
单克隆抗体MERS-4V2的重链如序列表的序列1所示,轻链如序列表的序列3所示。
序列表的序列1中,第1-16位氨基酸残基组成信号肽。序列表的序列1中,CDR1、CDR2和CDR3依次为第45-52位氨基酸残基、第70-77位氨基酸残基、第116-120位氨基酸残基。
序列表的序列3中,第1-16位氨基酸残基组成信号肽。序列表的序列3中,CDR1、CDR2和CDR3依次为第45-52位氨基酸残基、第70-72位氨基酸残基、第109-119位氨基酸残基。
单克隆抗体MERS-4V2能够特异结合MERS-CoV膜蛋白S的RBD。与单克隆抗体MERS-4相比,单克隆抗体MERS-4V2的表达量显著提高,对MERS-CoV的假型病毒的中和活性和广谱性也有提高。
实施例2、单克隆抗体的制备
一、构建重组质粒
1、合成双链DNA片段甲,然后将DNA片段甲插入pMD18-T载体,得到重组质粒甲。经测序验证,双链DNA片段甲中,5’末端至3’末端方向,依次由如下元件组成:CMV启动子(如序列表的序列7所示),单克隆抗体MERS-4的重链的编码基因(如序列表的序列6所示,编码序列表的序列5所示的重链),ployA(如序列表的序列8所示)。
2、合成双链DNA片段乙,然后将DNA片段乙插入pMD18-T载体,得到重组质粒乙。经测序验证,双链DNA片段乙中,5’末端至3’末端方向,依次由如下元件组成:CMV启动子(如序列表的序列7所示),单克隆抗体的轻链的编码基因(如序列表的序列4所示,编码序列表的序列3所示的轻链),ployA(如序列表的序列8所示)。
3、合成双链DNA片段丙,然后将DNA片段丙插入pMD18-T载体,得到重组质粒丙。经测序验证,双链DNA片段丙中,5’末端至3’末端方向,依次由如下元件组成:CMV启动子(如序列表的序列7所示),单克隆抗体MERS-4V2的重链的编码基因(如序列表的序列2所示,编码序列表的序列1所示的重链),ployA(如序列表的序列8所示)。
二、单克隆抗体MERS-4的制备
1、将重组质粒甲和重组质粒乙共转染293T细胞(转染剂量:每1×105个细胞转染2微克重组质粒甲和2微克重组质粒乙,采用的培养基为含10%FBS的DMEM培养基),37℃静置孵育8小时,然后将培养基更换为含2%FBS的DMEM培养基并37℃静置孵育72小时(实际应用中,48-72小时均可),然后收细胞培养上清,4℃、4000rpm离心1小时,收集上清液。
2、取步骤1得到的上清液,采用protein A beads(PierceTMProtein A Agarose;Thermo公司)纯化,然后采用10K超滤管浓缩并将蛋白缓冲体系更换为PBS缓冲液,得到MERS-4溶液。
MERS-4溶液的SDS-PAGE电泳图显示具有两个条带。分别回收两个条带并测序,一个条带的前10位氨基酸残基为序列表的序列5的前10位,另一个条带的前10位氨基酸残基为序列表的序列3的前10位。
检测MERS-4溶液的总蛋白含量,作为单克隆抗体MERS-4的含量。经计算,每L步骤1得到的上清液中含有1mg单克隆抗体MERS-4。
三、单克隆抗体MERS-4V2的制备
1、将重组质粒丙和重组质粒乙共转染293T细胞(转染剂量:每1×105个细胞转染2微克重组质粒丙和2微克重组质粒乙,采用的培养基为含10%FBS的DMEM培养基),37℃静置孵育8小时,然后将培养基更换为含2%FBS的DMEM培养基并37℃静置孵育72小时(实际应用中,48-72小时均可),然后收细胞培养上清,4℃、4000rpm离心1小时,收集上清液。
2、取步骤1得到的上清液,采用protein A beads(PierceTMProtein A Agarose;Thermo公司)纯化,然后采用10K超滤管浓缩并将蛋白缓冲体系更换为PBS缓冲液,得到MERS-4V2溶液。
MERS-4V2溶液的SDS-PAGE电泳图见图1,显示具有两个条带。分别回收两个条带并测序,一个条带的前10位氨基酸残基为序列表的序列1的前10位,另一个条带的前10位氨基酸残基为序列表的序列3的前10位。
检测MERS-4V2溶液的总蛋白含量,作为单克隆抗体MERS-4V2的含量。经计算,每L步骤1得到的上清液中含有10mg单克隆抗体MERS-4V2。
与MERS-4相比,在相同条件下MERS-4V2的产量提高至了10倍。
实施例3、单克隆抗体与RBD的结合特性
一、构建重组质粒
pFastBacTM dual载体本身不带有胞外分泌的信号肽,而RBD本身是分泌蛋白,因而需要连入信号肽。蛋白在昆虫细胞表达并分泌的过程中信号肽将被切除,最终获得的蛋白序列将不含信号肽。
用序列表的序列9所示的DNA分子代替pFastBacTM dual载体中的序列表的序列10所示的DNA分子,得到重组质粒。序列表的序列9中,第7-120位核苷酸编码gp67信号肽,第130-849位核苷酸编码RBD蛋白,第880-924位核苷酸编码AVi标签,第925-942位核苷酸编码His6标签。AVi标签可被生物素连接酶生物素化。
重组质粒在昆虫细胞表达并分泌的蛋白质如序列表的序列11所示,将其命名为RBD融合蛋白。
二、制备重组Bacmid
1、将步骤一构建的重组质粒和大肠杆菌DH10Bac感受态细胞混合后在冰上放置30min,然后42℃热激75s,然后冰上放置2min,然后加入500μl液体LB培养基,37℃,210rpm振荡复苏5小时。
2、完成步骤1后,吸取10μl涂布于含50μg/mL卡那霉素、7μg/mL庆大霉素、10μg/mL四环素、40μg/mLIPTG和100μg/mLX-gal的LB培养基平板,避光培养三天。
3、完成步骤2后,挑取白色单菌落,接种于含50μg/mL卡那霉素、7μg/mL庆大霉素的液体LB培养基,振荡培养16小时。
4、完成步骤3后,收集菌体,进行质粒提取,得到重组Bacmid。
三、制备重组病毒
1、在10cm培养皿培养Sf9细胞,27℃静置培养直至细胞贴壁(显微镜下观察,保证培养皿底部约有70%-80%被细胞覆盖),吸弃培养上清。
2、取15μ lCellfectin,用100μl昆虫细胞培养基稀释。
3、取步骤二得到的重组Bacmid(约1μg),用100μl昆虫细胞培养基稀释。
4、将步骤2得到的稀释液和步骤3得到的稀释液混匀,室温静置30min,然后用昆虫细胞培养基稀释至2ml。
5、将步骤4得到的稀释液滴加至完成步骤1的底部覆盖细胞的培养皿中,静置培养5小时,然后吸弃培养上清,加入7ml新鲜的昆虫细胞培养基,用封口膜密封于27℃静置培养7天(实际应用中,7-10天均可)。
6、完成步骤5后,吸取培养上清,即为P0代病毒液。
7、用昆虫细胞培养基培养Sf9细胞至细胞密度为2×106/mL,然后加入P0代病毒液(病毒液与细胞液的体积比为1:1000),27℃静置培养5天,吸取培养上清,即为P1代病毒液。
四、制备蛋白
1、用昆虫细胞培养基培养Sf9细胞至细胞密度为2×106/ml,然后加入P1代病毒液(病毒液与细胞液的体积比为1∶100),27℃静置培养72小时(实际应用中,48-96小时均可),然后4000rpm离心15min,收集上清液。
2、取步骤1得到的上清液,采用双层0.45μm的玻璃纤维膜进行抽滤,收集滤液。
3、取步骤2得到的滤液,采用切向流超滤系统进行浓缩,然后将蛋白置换到上样缓冲液中,然后13000rpm离心30min,收集上清液。
上样缓冲液(pH7.2):含10mM HEPAS,150mM NaCl,余量为水。
4、取步骤3得到的上清液,加入镍柱beads,4℃孵育5小时,然后离心弃除上清液,用含有洗涤液充分淋洗beads,然后用洗脱液洗脱并收集洗脱液。
洗涤液(pH7.2):含20mM咪唑、10mM HEPAS,150mM NaCl,余量为水。
洗脱液(pH7.2):含500mM咪唑、、10mM HEPAS,150mM NaCl,余量为水。
5、取步骤4得到的洗脱液,使用10kD浓缩管进行浓缩,得到浓缩液,即为RBD融合蛋白溶液。
五、生物素标记
取步骤四得到的RBD融合蛋白溶液,采用GeneCopoeia的Biotin Ligase(生物素连接酶)试剂盒标记(产品编号:B0101A)进行生物素标记,得到生物素标记的RBD融合蛋白。
六、检测单克隆抗体与生物素标记的RBD融合蛋白的结合活性。
1、取96孔酶标板,每孔加入100μl包被液(含100ng步骤四制备的RBD融合蛋白),4℃静置过夜。
2、完成步骤1后,取所述96孔酶标板,每孔加入200μl封闭液(含10%FBS的PBS缓冲液),37℃静置2小时,然后用PBST溶液洗涤3次。
3、完成步骤2后,取所述96孔酶标板,加入待测溶液37℃孵育1小时,然后用PBST溶液洗涤3次。待测溶液的加入量每孔为100μl。待测溶液为实施例2制备的MERS-4溶液或MERS-4V2溶液或他们各自的稀释液,蛋白浓度依次为10μg/ml、5μg/ml、2.5μg/ml、1.25μg/ml、0.625μg/ml,每种溶液的每个浓度设置3个复孔。
4、完成步骤3后,取所述96孔酶标板,每孔加入100μl anti-human-HRP(工作浓度为1∶3000),37℃孵育1小时,然后用PBST溶液洗涤3次。
5、每孔加入100μl显色液,避光静置4分钟,然后每孔加入50μl终止液,用酶标仪测量450nm波长的OD值。
结果见图2,与MERS-4相比,MERS-4V2抗体的结合活性显著提高。
七、检测单克隆抗体与生物素标记的RBD融合蛋白的亲和力。
结果见表1。单克隆抗体MERS-4的Kd值是单克隆抗体MERS-4V2的Kd值的1.71倍(Kd值越低表示亲和力越好)。
表1结合和解离常数
K<sub>on</sub>(M<sup>-1</sup>s<sup>-1</sup>) | K<sub>off</sub>(S<sup>-1</sup>) | K<sub>a</sub>(M<sup>-1</sup>) | K<sub>d</sub>(M) | |
MERS-4 | 8.05E+05 | 1.01E-03 | 8.00E+08 | 1.25E-09 |
MERS-4V2 | 4.21E+05 | 3.08E-04 | 1.37E+09 | 7.32E-10 |
实施例4、单克隆抗体对MERS-CoV突变假病毒的广谱中和活性
一、MERS-CoV假病毒的制备
表达MERS-CoV全长膜蛋白的质粒(命名为MERS-CoV膜蛋白质粒)和骨架质粒pNL4-3R-E-luciferase共转染293T细胞,孵育后能够得到具有感染性但没有复制能力的MERS-CoV假型病毒,其感染性同活病毒相似。
将序列表的序列12所示的双链DNA分子(MERS-CoV全长膜蛋白的编码基因)插入pcDNA3.1(+)载体的HindIII和XhoI酶切位点之间,得到MERS-CoV膜蛋白质粒。
将MERS-CoV膜蛋白质粒和骨架质粒pNL4-3R-E-luciferase共转染293T细胞,37℃静置孵育,转染48小时后收集细胞培养上清,即为含有MERS-CoV假病毒的病毒液(简称MERS-CoV病毒液)。利用p24定量检测的ELISA试剂盒(HIV P24抗原定量检测试剂盒,KEY-BIO,96T)检测MERS-CoV病毒液的病毒滴度,MERS-CoV病毒液的OD450nm(吸光值为1(1021TCID50/ml),吸光值越大说明病毒含量越高。
二、各个MERS-CoV假病毒突变体的制备
病毒在感染过程中为了逃逸免疫压力或者快速扩增,其基因会发生一定的变异,MERS-CoV也不例外。通过NCBI查找已公布的MERS-CoV病毒序列,进行比对,找到在RBD上发生的突变;利用定点突变的方法将找到的突变位点引入MERS-CoV全长膜蛋白的编码基因上,按步骤一中的假病毒包装方法进行假病毒包装,得到各个MERS-CoV假病毒突变体。
将序列表的序列12第1270-1272位核苷酸由“act”突变为“ATT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到T424I突变体。
将序列表的序列12第1378-1380位核苷酸由“tct”突变为“TTT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到S460F突变体。
将序列表的序列12第1516-1518位核苷酸由“ctg”突变为“TTT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到L506F突变体。
将序列表的序列12第1525-1527位核苷酸由“gat”突变为“GGT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到D509G突变体。
将序列表的序列12第1531-1533位核苷酸由agg“”突变为“CCT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到R511P突变体。
将序列表的序列12第1558-1560位核苷酸由“gcc”突变为“TCT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到A520S突变体。
将序列表的序列12第1564-1566位核苷酸由“caa”突变为“CAT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到Q522H突变体。
将序列表的序列12第1609-1611位核苷酸由“gat”突变为“GAA”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到D537E突变体。
将序列表的序列12第1666-1668位核苷酸由“gca”突变为“GTT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到A556V突变体。
将序列表的序列12第1678-1680位核苷酸由“aca”突变为“ATT”,用突变后的DNA分子代替序列表的序列12所示的DNA分子,按照步骤一的方法制备得到T560I突变体。
二、检测单克隆抗体对MERS-CoV假病毒的中和活性
待测溶液为:MERS-4溶液或MERS-4V2溶液。
(1)采用含10%FBS的DMEM培养基将待测溶液倍比稀释,依次得到蛋白浓度为50.000000μg/ml、16.666670μg/ml、5.555555μg/ml、1.851852μg/ml、0.6172839μg/ml、0.2057613μg/ml、0.06858711μg/ml、0.02286237μg/ml、0.00762079μg/ml、0.002540263μg/ml、0.000846754μg/ml、0.000282251μg/ml、0.0000940838μg/ml、0.0000313613μg/ml、0.0000104538μg/ml和0.00000348459μg/ml的稀释液。
(2)将100微升步骤(1)得到的稀释液与50微升病毒液(病毒含量为100TCID50)混合,37℃静置孵育1小时。设置用100微升含10%FBS的DMEM培养基代替100微升稀释液的空白对照。病毒液为步骤一制备的MERS-CoV病毒液或步骤二制备的突变体病毒液。
(3)完成步骤(2)后,加入50微升Huh7细胞的细胞液(约含2×104个Huh7细胞),37℃静置孵育48小时(实际应用中,48-72小时均可)。
(4)完成步骤(3)后,加入100μlPBS缓冲液和50μl细胞裂解液(Bright-GloTMLuciferase Assay System,Promega,E2650),静置2min,然后用化学发光仪检测荧光素酶活性。
每种处理设置5个复孔,结果取平均值。
中和活性=(空白对照组的荧光强度-加入稀释液的实验组的荧光强度)/空白对照组的荧光强度×100%。
中和活性为50%时对应的稀释液中的蛋白浓度即为IC50值。
结果见表2。与MERS-4相比,MERS-4V2抗体的广谱中和活性得到了提高。
表2抗体的广谱中和活性检测结果
SEQUENCE LISTING
<110> 清华大学
<120> 单克隆抗体MERS-4V2及其编码基因和应用
<130> CGGNQAYX-176111
<160> 12
<170> PatentIn version 3.5
<210> 1
<211> 461
<212> PRT
<213> Artificial sequence
<400> 1
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
35 40 45
Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
50 55 60
Glu Trp Val Ala Leu Ile Ser Tyr Asp Ile Ser Thr Asp Tyr Tyr Ala
65 70 75 80
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
85 90 95
Thr Ile Tyr Leu Gln Met Asn Asn Leu Arg Thr Glu Asp Thr Ala Leu
100 105 110
Tyr Tyr Cys Thr Asn Thr Tyr Tyr Trp Gly Gln Gly Thr Leu Val Thr
115 120 125
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
130 135 140
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
145 150 155 160
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
165 170 175
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
180 185 190
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
195 200 205
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
210 215 220
Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
225 230 235 240
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
245 250 255
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
260 265 270
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
275 280 285
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
290 295 300
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
305 310 315 320
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
325 330 335
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
340 345 350
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
355 360 365
Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
370 375 380
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
385 390 395 400
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
405 410 415
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
420 425 430
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
435 440 445
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 2
<211> 1386
<212> DNA
<213> Artificial sequence
<400> 2
atgggatggt catgtatcat cctttttcta gtagcaactg caaccggtgt acattctgag 60
gtgcagctgg tggagtctgg gggaggcctg gtccagcctg ggaggtccct gagactctcc 120
tgtgcagcct ctggattcac cttcagtaac tatgctatgt actgggtccg ccaggctcca 180
ggcaaggggc tggagtgggt ggcacttata tcatatgata taagcactga ctactacgca 240
gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac gatatatctg 300
caaatgaata atctgagaac tgaggacacg gctttgtatt actgtacgaa cacctactac 360
tggggccagg gaaccctggt caccgtctcc tcagcgtcga ccaagggccc atcggtcttc 420
cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc 480
aaggactact tccccgaacc tgtgacggtc tcgtggaact caggcgccct gaccagcggc 540
gtgcacacct tcccggctgt cctacagtcc tcaggactct actccctcag cagcgtggtg 600
accgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc 660
agcaacacca aggtggacaa gagagttgag cccaaatctt gtgacaaaac tcacacatgc 720
ccaccgtgcc cagcacctga actcctgggg ggaccgtcag tcttcctctt ccccccaaaa 780
cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg 840
agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat 900
gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc 960
accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 1020
gccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 1080
caggtgtaca ccctgccccc atcccgggag gagatgacca agaaccaggt cagcctgacc 1140
tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1200
ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc 1260
tatagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1320
gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtccccgggt 1380
aaatga 1386
<210> 3
<211> 235
<212> PRT
<213> Artificial sequence
<400> 3
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
Ser Trp Ala Gln Ser Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr
20 25 30
Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile
35 40 45
Gly Asn Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro
50 55 60
Lys Leu Leu Ile Tyr Trp Asn Asp Gln Arg Pro Ser Gly Val Pro Asp
65 70 75 80
Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser
85 90 95
Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp
100 105 110
Asp Ser Leu Ser Gly Ala Val Phe Gly Gly Gly Thr Gln Leu Thr Val
115 120 125
Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser
130 135 140
Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser
145 150 155 160
Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser
165 170 175
Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn
180 185 190
Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp
195 200 205
Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr
210 215 220
Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
225 230 235
<210> 4
<211> 708
<212> DNA
<213> Artificial sequence
<400> 4
atgggatggt catgtatcat cctttttcta gtagcaactg caaccggttc ctgggcccag 60
tctgtgctga ctcagtcacc ctcagcgtct gggacccccg ggcagagggt caccatctct 120
tgttctggaa gcagctccaa catcggaaat aattatgtat actggtacca gcaactccca 180
ggaacggccc ccaaactcct catctattgg aatgatcagc ggccctcagg ggtccctgac 240
cgattctctg gctccaagtc tggcacctca gcctccctgg ccatcagtgg gctccggtcc 300
gaggatgagg ctgattatta ctgtgcagca tgggatgaca gcctgagtgg tgcagtgttc 360
ggaggaggca cccagctgac cgtcctcggt cagcccaagg ctgccccctc ggtcactctg 420
ttcccgccct cgagtgagga gcttcaagcc aacaaggcca cactggtgtg tctcataagt 480
gacttctacc cgggagccgt gacagtggcc tggaaggcag atagcagccc cgtcaaggcg 540
ggagtggaga ccaccacacc ctccaaacaa agcaacaaca agtacgcggc cagcagctac 600
ctgagcctga cgcctgagca gtggaagtcc cacagaagct acagctgcca ggtcacgcat 660
gaagggagca ccgtggagaa gacagtggcc cctacagaat gttcatag 708
<210> 5
<211> 461
<212> PRT
<213> Artificial sequence
<400> 5
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
20 25 30
Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
35 40 45
Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
50 55 60
Glu Trp Val Ala Leu Ile Ser Tyr Asp Ile Ser Thr Asp Tyr Tyr Ala
65 70 75 80
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
85 90 95
Thr Ile Tyr Leu Gln Met Asn Asn Leu Arg Thr Glu Asp Thr Ala Leu
100 105 110
Tyr Tyr Cys Ala Gly Asn Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
115 120 125
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
130 135 140
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
145 150 155 160
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
165 170 175
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
180 185 190
Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
195 200 205
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
210 215 220
Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
225 230 235 240
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
245 250 255
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
260 265 270
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
275 280 285
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
290 295 300
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
305 310 315 320
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
325 330 335
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
340 345 350
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
355 360 365
Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
370 375 380
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
385 390 395 400
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
405 410 415
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
420 425 430
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
435 440 445
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
450 455 460
<210> 6
<211> 1386
<212> DNA
<213> Artificial sequence
<400> 6
atgggatggt catgtatcat cctttttcta gtagcaactg caaccggtgt acattctgag 60
gtgcagctgg tggagtctgg gggaggcctg gtccagcctg ggaggtccct gagactctcc 120
tgtgcagcct ctggattcac cttcagtaac tatgctatgt actgggtccg ccaggctcca 180
ggcaaggggc tggagtgggt ggcacttata tcatatgata taagcactga ctactacgca 240
gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac gatatatctg 300
caaatgaata atctgagaac tgaggacacg gctttgtatt actgtgcggg taatgactac 360
tggggccagg gaaccctggt caccgtctcc tcagcgtcga ccaagggccc atcggtcttc 420
cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc 480
aaggactact tccccgaacc tgtgacggtc tcgtggaact caggcgccct gaccagcggc 540
gtgcacacct tcccggctgt cctacagtcc tcaggactct actccctcag cagcgtggtg 600
accgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc 660
agcaacacca aggtggacaa gagagttgag cccaaatctt gtgacaaaac tcacacatgc 720
ccaccgtgcc cagcacctga actcctgggg ggaccgtcag tcttcctctt ccccccaaaa 780
cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg 840
agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat 900
gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc 960
accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 1020
gccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 1080
caggtgtaca ccctgccccc atcccgggag gagatgacca agaaccaggt cagcctgacc 1140
tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1200
ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc 1260
tatagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1320
gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtccccgggt 1380
aaatga 1386
<210> 7
<211> 888
<212> DNA
<213> Artificial sequence
<400> 7
agtaatcaat tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac 60
ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa 120
tgacgtatgt tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 180
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 240
ctattgacgt caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat 300
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atggtgatgc 360
ggttttggca gtacatcaat gggcgtggat agcggtttga ctcacgggga tttccaagtc 420
tccaccccat tgacgtcaat gggagtttgt tttggcacca aaatcaacgg gactttccaa 480
aatgtcgtaa caactccgcc ccattgacgc aaatgggcgg taggcgtgta cggtgggagg 540
tctatataag cagagctcgt ttagtgaacc gtcagatcgc ctggagacgc catccacgct 600
gttttgacct ccatagaaga caccgggacc gatccagcct ccgcggccgg gaacggtgca 660
ttggaacgcg gattccccgt gccaagagtg acgtaagtac cgcctataga gtctataggc 720
ccaccccctt ggcttcgtta gaacgcggct acaattaata cataacctta tgtatcatac 780
acatacgatt taggtgacac tatagaataa catccacttt gcctttctct ccacaggtgt 840
ccactcccag gtccaactgc acctcggttc tatcgattga attccacc 888
<210> 8
<211> 128
<212> DNA
<213> Artificial sequence
<400> 8
aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac aaatttcaca 60
aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct 120
tatcatgt 128
<210> 9
<211> 945
<212> DNA
<213> Artificial sequence
<400> 9
ggatctatgc tactagtaaa tcagtcacac caaggcttca ataaggaaca cacaagcaag 60
atggtaagcg ctattgtttt atatgtgctt ttggcggcgg cggcgcattc tgcctttgcg 120
gcggatcccg aggctaagcc atctggctct gtggtggaac aggctgaggg agtggagtgt 180
gacttcagcc cactgctgtc tggcacacct ccacaggtct acaacttcaa gagactggtg 240
ttcaccaact gtaactacaa cctgaccaaa ctgctgtccc tgttctctgt gaatgacttc 300
acttgtagcc agattagccc tgctgccatt gccagcaact gttactcctc cctgattctg 360
gactacttct cctacccact gagtatgaag tctgacctgt ctgtgtcctc tgctggacca 420
atcagccagt tcaactacaa gcagtccttc agcaacccaa cttgtctgat tctggctaca 480
gtgccacaca acctgaccac catcaccaag ccactgaaat actcctacat caacaagtgt 540
agcagactgc tgtctgatga caggacagag gtgccacaac tagtgaatgc caaccaatac 600
agcccatgtg tgagcattgt gccaagcaca gtgtgggagg atggagacta ctacaggaag 660
caacttagcc cattggaggg aggaggctgg ctggtggcat ctggcagcac agtggctatg 720
acagaacaac tccaaatggg ctttggcatc acagtccaat atggcacaga caccaactct 780
gtgtgtccaa aattggagtt tgccaatgac accaagattg ccagccaact tggcaactgt 840
gtggaatacg ggtcgacgag ctcactagtc gcggccgcgc tgcatcatat tctcgacgca 900
cagaaaatgg tgtggaatca tcgtcatcat caccaccatc attaa 945
<210> 10
<211> 93
<212> DNA
<213> Artificial sequence
<400> 10
ggatcccggt ccgaagcgcg cggaattcaa aggcctacgt cgacgagctc actagtcgcg 60
gccgctttcg aatctagagc ctgcagtctc gac 93
<210> 11
<211> 264
<212> PRT
<213> Artificial sequence
<400> 11
Ala Asp Pro Glu Ala Lys Pro Ser Gly Ser Val Val Glu Gln Ala Glu
1 5 10 15
Gly Val Glu Cys Asp Phe Ser Pro Leu Leu Ser Gly Thr Pro Pro Gln
20 25 30
Val Tyr Asn Phe Lys Arg Leu Val Phe Thr Asn Cys Asn Tyr Asn Leu
35 40 45
Thr Lys Leu Leu Ser Leu Phe Ser Val Asn Asp Phe Thr Cys Ser Gln
50 55 60
Ile Ser Pro Ala Ala Ile Ala Ser Asn Cys Tyr Ser Ser Leu Ile Leu
65 70 75 80
Asp Tyr Phe Ser Tyr Pro Leu Ser Met Lys Ser Asp Leu Ser Val Ser
85 90 95
Ser Ala Gly Pro Ile Ser Gln Phe Asn Tyr Lys Gln Ser Phe Ser Asn
100 105 110
Pro Thr Cys Leu Ile Leu Ala Thr Val Pro His Asn Leu Thr Thr Ile
115 120 125
Thr Lys Pro Leu Lys Tyr Ser Tyr Ile Asn Lys Cys Ser Arg Leu Leu
130 135 140
Ser Asp Asp Arg Thr Glu Val Pro Gln Leu Val Asn Ala Asn Gln Tyr
145 150 155 160
Ser Pro Cys Val Ser Ile Val Pro Ser Thr Val Trp Glu Asp Gly Asp
165 170 175
Tyr Tyr Arg Lys Gln Leu Ser Pro Leu Glu Gly Gly Gly Trp Leu Val
180 185 190
Ala Ser Gly Ser Thr Val Ala Met Thr Glu Gln Leu Gln Met Gly Phe
195 200 205
Gly Ile Thr Val Gln Tyr Gly Thr Asp Thr Asn Ser Val Cys Pro Lys
210 215 220
Leu Glu Phe Ala Asn Asp Thr Lys Ile Ala Ser Gln Leu Gly Asn Cys
225 230 235 240
Val Glu Tyr Leu His His Ile Leu Asp Ala Gln Lys Met Val Trp Asn
245 250 255
His Arg His His His His His His
260
<210> 12
<211> 4062
<212> DNA
<213> Artificial sequence
<400> 12
atgattcact ctgtgttcct gctgatgttc ctgctgacac caacagagtc ctatgtggat 60
gtgggacctg actctgtgaa gtctgcctgt attgaggtgg acatccaaca gaccttcttt 120
gacaagacct ggccaagacc aattgatgtg agcaaggctg atggcatcat ctacccacag 180
ggcaggacct acagcaacat caccatcacc taccagggac tgtttccata ccagggagat 240
catggagata tgtatgtcta ctctgctggt catgccacag gcaccacacc acagaaactg 300
tttgtggcta actacagcca ggatgtgaag cagtttgcca atggctttgt ggtgaggatt 360
ggagcagcag ccaacagcac aggcacagtg attatcagcc caagcacctc tgccaccatc 420
aggaagattt accctgcctt tatgctgggc tcctctgtgg gcaacttctc tgatggcaag 480
atgggcaggt tcttcaacca caccctggtg ctgctgcctg atggctgtgg caccctgctg 540
agggctttct actgtatctt ggaaccaagg tctggcaacc actgtcctgc tggcaactcc 600
tacacctcct ttgccaccta ccacacacct gccacagact gttctgatgg caactacaac 660
aggaatgcct ccctgaactc cttcaaggaa tacttcaacc tgaggaactg tacctttatg 720
tacacctaca acatcacaga ggatgagatt ttggagtggt ttggcatcac ccagacagcc 780
cagggagtgc atctgttctc gagcagatat gtggacctct atggaggcaa tatgttccag 840
tttgccaccc tgcctgtcta tgacaccatc aaatactaca gcatcatccc acacagcatc 900
aggagcatcc agtctgacag gaaggcttgg gctgccttct atgtctacaa actccaacca 960
ctgaccttcc tgctggactt ctctgtggat ggctacatca ggagggctat tgactgtggc 1020
ttcaatgacc tgagccaact tcactgttcc tatgagtcct ttgatgtgga gtctggagtc 1080
tactctgtgt cctcctttga ggctaagcca tctggctctg tggtggaaca ggctgaggga 1140
gtggagtgtg acttcagccc actgctgtct ggcacacctc cacaggtcta caacttcaag 1200
agactggtgt tcaccaactg taactacaac ctgaccaaac tgctgtccct gttctctgtg 1260
aatgacttca cttgtagcca gattagccct gctgccattg ccagcaactg ttactcctcc 1320
ctgattctgg actacttctc ctacccactg agtatgaagt ctgacctgtc tgtgtcctct 1380
gctggaccaa tcagccagtt caactacaag cagtccttca gcaacccaac ttgtctgatt 1440
ctggctacag tgccacacaa cctgaccacc atcaccaagc cactgaaata ctcctacatc 1500
aacaagtgta gcagactgct gtctgatgac aggacagagg tgccacaact agtgaatgcc 1560
aaccaataca gcccatgtgt gagcattgtg ccaagcacag tgtgggagga tggagactac 1620
tacaggaagc aacttagccc attggaggga ggaggctggc tggtggcatc tggcagcaca 1680
gtggctatga cagaacaact ccaaatgggc tttggcatca cagtccaata tggcacagac 1740
accaactctg tgtgtccaaa attggagttt gccaatgaca ccaagattgc cagccaactt 1800
ggcaactgtg tggaatactc cctctatgga gtgtctggca ggggagtgtt ccagaactgt 1860
actgctgtgg gagtgagaca acagaggttt gtctatgatg cctaccagaa cctggtgggc 1920
tactactctg atgatggcaa ctactactgt ctgagggctt gtgtgtctgt gcctgtgtct 1980
gtgatttatg acaaggagac caagacccat gccaccctgt ttggatccgt ggcttgtgaa 2040
cacatctcca gcacaatgag tcaatacagc aggagcacca ggagtatgct gaaaaggagg 2100
gacagcacat atggaccact ccaaacacct gtgggctgtg tgctgggact ggtgaactcc 2160
tccctgtttg tggaggactg taaactgcca ctgggacaat ccctgtgtgc cctgcctgac 2220
acaccaagca ccctgacacc aaggtctgtg aggtctgtgc ctggagagat gagactggca 2280
agcattgcct tcaaccaccc aatccaggtg gaccaactta actcctccta cttcaaactg 2340
agcatcccaa ccaacttctc ctttggagtg acccaggaat acatccagac caccatccag 2400
aaggtgacag tggactgtaa gcaatatgtg tgtaatggct tccagaagtg tgaacaactt 2460
ctgagggaat atggacaatt ctgtagcaag ataaaccagg ctcttcatgg agccaacctg 2520
agacaggatg actctgtgag gaacctgttt gcctctgtga agtccagcca gtccagccca 2580
atcatccctg gctttggagg agacttcaac ctgaccctgt tggaaccggt gagcatcagc 2640
acaggcagca ggtctgccag gtctgccatt gaggacctgc tgtttgacaa ggtgaccatt 2700
gctgaccctg gctatatgca gggctatgat gactgtatgc aacagggacc tgcctctgcc 2760
agggacctga tttgtgccca atatgtggct ggctacaagg tgctgcctcc actgatggat 2820
gtgaatatgg aggctgccta cacctcctcc ctgctgggca gcattgctgg agtgggctgg 2880
actgcaggac tgtcctcctt tgctgccatc ccatttgccc agagcatctt ctacagactg 2940
aatggagtgg gcatcaccca acaggtgctg tctgagaacc agaaactgat tgccaacaag 3000
ttcaaccagg ctctgggagc tatgcagaca ggcttcacca ccaccaatga ggctttccag 3060
aaggtccagg atgctgtgaa caacaatgcc caggctctga gcaaactggc atctgaactg 3120
agcaacacct ttggagccat ctctgctagc attggagaca tcatccagag actggatgtg 3180
ttggaacagg atgcccagat tgacagactg ataaatggca gactgaccac cctgaatgcc 3240
tttgtggctc aacaacttgt gaggtctgag tctgctgccc tgtctgccca acttgccaag 3300
gacaaggtga atgagtgtgt gaaggctcaa agcaagaggt ctggcttctg tggacaaggc 3360
acccacattg tgtcctttgt ggtgaatgcc ccaaatggac tctactttat gcatgtgggc 3420
tactacccaa gcaaccacat tgaggtggtg tctgcctatg gactgtgtga tgctgccaac 3480
ccaaccaact gtattgcccc tgtgaatggc tacttcatca agaccaacaa caccaggatt 3540
gtggatgagt ggtcctacac aggctcctcc ttctatgccc ctgaaccaat cacctccctg 3600
aacaccaaat atgtggctcc acaggtgacc taccagaaca tcagcaccaa cctgcctcct 3660
ccactgctgg gcaacagcac aggcattgac ttccaggatg aactggatga gttcttcaag 3720
aatgtgagca ccagcatccc aaactttggc tccctgaccc agataaacac caccctgctg 3780
gacctgacct atgagatgct gtccctccaa caggtggtga aggctctgaa tgagtcctac 3840
attgacctga aagaactggg caactacacc tactacaaca agtggccatg gtacatctgg 3900
ctgggattca ttgcaggact ggtggccctg gctctgtgcg tcttctttat cctgtgctgt 3960
accggctgcg ggacaaactg tatggggaag ctgaaatgta atcggtgctg tgacagatac 4020
gaggaatatg atctggagcc ccacaaggtg cacgtccatt aa 4062
Claims (10)
1.一种IgG抗体,由重链和轻链组成;所述重链中的重链可变区中的CDR1、CDR2和CDR3依次为序列表的序列1自N末端第45-52位氨基酸残基、第70-77位氨基酸残基和第116-120位氨基酸残基;所述轻链中的轻链可变区中的CDR1、CDR2和CDR3依次为序列表的序列3自N末端第45-52位氨基酸残基、第70-72位氨基酸残基和第109-119位氨基酸残基。
2.如权利要求1所述的IgG抗体,其特征在于:
所述重链中的重链可变区为如下(a1)或(a2):(a1)序列表的序列1自N末端第17-131位氨基酸残基组成的蛋白质;(a2)序列表的序列1自N末端第1-131位氨基酸残基组成的蛋白质;
所述轻链中的轻链可变区为如下(b1)或(b2):(b1)序列表的序列3自N末端第17-129位氨基酸残基组成的蛋白质;(b2)序列表的序列3自N末端第1-129位氨基酸残基组成的蛋白质。
3.如权利要求2所述的IgG抗体,其特征在于:
所述重链为如下(c1)或(c2):(c1)序列表的序列1自N末端第17-461位氨基酸残基组成的蛋白质;(c2)序列表的序列3所示的蛋白质;
所述轻链为如下(d1)或(d2):(d1)序列表的序列3自N末端第17-235位氨基酸残基组成的蛋白质;(d2)序列表的序列3所示的蛋白质。
4.编码权利要求2所述IgG抗体的基因,其特征在于:
编码所述重链的基因为如下(1)或(2):
(1)序列表的序列2自5’末端第49-1383位核苷酸所示的DNA分子;
(2)序列表的序列2所示的DNA分子;
编码所述轻链的基因为如下(3)或(4):
(3)序列表的序列4自5’末端第49-705位核苷酸所示的DNA分子;
(4)序列表的序列4所示的DNA分子。
5.权利要求1或2或3所述IgG抗体在制备用于抑制中东呼吸综合征冠状病毒的药物中的应用。
6.一种用于抑制中东呼吸综合征冠状病毒的药物,其活性成分为权利要求1或2或3所述IgG抗体。
7.权利要求1或2或3所述IgG抗体在制备用于中和中东呼吸综合征冠状病毒的药物中的应用。
8.一种用于中和中东呼吸综合征冠状病毒的药物,其活性成分为权利要求1或2或3所述IgG抗体。
9.权利要求1或2或3所述IgG抗体在制备用于预防和/或治疗中东呼吸综合征的药物中的应用。
10.一种用于预防和/或治疗中东呼吸综合征的药物,其活性成分为权利要求1或2或3所述IgG抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710951002.2A CN109666070B (zh) | 2017-10-13 | 2017-10-13 | 单克隆抗体mers-4v2及其编码基因和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710951002.2A CN109666070B (zh) | 2017-10-13 | 2017-10-13 | 单克隆抗体mers-4v2及其编码基因和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109666070A true CN109666070A (zh) | 2019-04-23 |
CN109666070B CN109666070B (zh) | 2021-02-19 |
Family
ID=66138755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710951002.2A Active CN109666070B (zh) | 2017-10-13 | 2017-10-13 | 单克隆抗体mers-4v2及其编码基因和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109666070B (zh) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111190005A (zh) * | 2020-02-23 | 2020-05-22 | 重庆新赛亚生物科技有限公司 | 新型冠状病毒抗体检测用检测试剂卡及其制备方法 |
CN111189900A (zh) * | 2020-02-21 | 2020-05-22 | 云南大学 | 一种新型冠状病毒2019-nCoV的电化学检测方法 |
CN111269313A (zh) * | 2020-03-07 | 2020-06-12 | 北京岳昊科技发展有限公司 | 一种用于检测新型冠状病毒的单克隆抗体及其制备试剂盒的用途 |
CN111303279A (zh) * | 2020-03-17 | 2020-06-19 | 中国医学科学院病原生物学研究所 | 一种针对新型冠状病毒的单域抗体及其应用 |
CN111592595A (zh) * | 2020-04-27 | 2020-08-28 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用 |
CN111620946A (zh) * | 2020-05-09 | 2020-09-04 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 分离的新型冠状病毒单克隆抗体或其抗原结合部分 |
CN111647076A (zh) * | 2020-04-27 | 2020-09-11 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 |
CN111690059A (zh) * | 2020-06-19 | 2020-09-22 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1D7 |
CN111718411A (zh) * | 2020-06-19 | 2020-09-29 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1F2 |
CN112500481A (zh) * | 2020-11-29 | 2021-03-16 | 山西省人民医院 | 一种人源抗新型冠状病毒的中和活性单克隆抗体 |
CN113354729A (zh) * | 2020-03-06 | 2021-09-07 | 深圳市第三人民医院 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
WO2021174594A1 (zh) * | 2020-03-06 | 2021-09-10 | 深圳市第三人民医院 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
WO2021180218A1 (zh) * | 2020-03-13 | 2021-09-16 | 北京大学 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
CN113493506A (zh) * | 2020-03-20 | 2021-10-12 | 腾盛华创医药技术(北京)有限公司 | 新型冠状病毒抗体及其应用 |
WO2021228135A1 (zh) * | 2020-05-13 | 2021-11-18 | 北京大学 | 制备抗原结合单元的方法 |
WO2021244601A1 (zh) * | 2020-06-04 | 2021-12-09 | 山东博安生物技术股份有限公司 | SARS-CoV-2病毒的中和抗体及其应用 |
CN113912708A (zh) * | 2021-09-01 | 2022-01-11 | 中国人民解放军军事科学院军事医学研究院 | 单域重链抗体及其编码基因和制备方法及应用和药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140161822A1 (en) * | 2012-11-13 | 2014-06-12 | Genentech, Inc. | Anti-hemagglutinin antibodies and methods of use |
CN104447986A (zh) * | 2014-12-23 | 2015-03-25 | 中国科学院微生物研究所 | 一种中东呼吸综合征冠状病毒中和抗体及其制备方法 |
CN104628848A (zh) * | 2013-11-14 | 2015-05-20 | 清华大学 | 单克隆抗体mers-27及其编码基因和应用 |
CN104628849A (zh) * | 2013-11-14 | 2015-05-20 | 清华大学 | 单克隆抗体mers-4及其编码基因和应用 |
-
2017
- 2017-10-13 CN CN201710951002.2A patent/CN109666070B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140161822A1 (en) * | 2012-11-13 | 2014-06-12 | Genentech, Inc. | Anti-hemagglutinin antibodies and methods of use |
CN104628848A (zh) * | 2013-11-14 | 2015-05-20 | 清华大学 | 单克隆抗体mers-27及其编码基因和应用 |
CN104628849A (zh) * | 2013-11-14 | 2015-05-20 | 清华大学 | 单克隆抗体mers-4及其编码基因和应用 |
CN104447986A (zh) * | 2014-12-23 | 2015-03-25 | 中国科学院微生物研究所 | 一种中东呼吸综合征冠状病毒中和抗体及其制备方法 |
Non-Patent Citations (6)
Title |
---|
JIUYANG XU 等: ""Antibodies and vaccines against Middle East respiratory syndrome coronavirus"", 《EMERG MICROBES INFECT》 * |
SENYANZHANG 等: ""Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein"", 《CELL REPORTS》 * |
WANG,X.Q. 等: ""Chain H, Heavy chain"", 《GENBANK》 * |
张林琦 等: ""MERS-CoV表面刺突蛋白与中和抗体MERS-27的作用机制研究"", 《第十一届全国病毒学学术研讨会暨第六届武汉现代病毒学国际研讨会论文集》 * |
张森燕: ""MERS-CoV RBD蛋白与中和抗体MERS-4及其变体的作用机制研究"", 《中国博士学位论文全文数据库(电子期刊) 医药卫生科技辑》 * |
王年爽: ""中东呼吸综合征冠状病毒MERS-CoV的受体识别机制研究"", 《中国博士学位论文全文数据库(电子期刊) 医药卫生科技辑》 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111189900A (zh) * | 2020-02-21 | 2020-05-22 | 云南大学 | 一种新型冠状病毒2019-nCoV的电化学检测方法 |
CN111189900B (zh) * | 2020-02-21 | 2020-10-27 | 云南大学 | 一种新型冠状病毒2019-nCoV的电化学检测方法 |
CN111190005A (zh) * | 2020-02-23 | 2020-05-22 | 重庆新赛亚生物科技有限公司 | 新型冠状病毒抗体检测用检测试剂卡及其制备方法 |
CN113354729A (zh) * | 2020-03-06 | 2021-09-07 | 深圳市第三人民医院 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
WO2021174594A1 (zh) * | 2020-03-06 | 2021-09-10 | 深圳市第三人民医院 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
CN111269313A (zh) * | 2020-03-07 | 2020-06-12 | 北京岳昊科技发展有限公司 | 一种用于检测新型冠状病毒的单克隆抗体及其制备试剂盒的用途 |
WO2021180218A1 (zh) * | 2020-03-13 | 2021-09-16 | 北京大学 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
CN111303279A (zh) * | 2020-03-17 | 2020-06-19 | 中国医学科学院病原生物学研究所 | 一种针对新型冠状病毒的单域抗体及其应用 |
CN113493506A (zh) * | 2020-03-20 | 2021-10-12 | 腾盛华创医药技术(北京)有限公司 | 新型冠状病毒抗体及其应用 |
CN111592595A (zh) * | 2020-04-27 | 2020-08-28 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用 |
CN111647076A (zh) * | 2020-04-27 | 2020-09-11 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用 |
CN111620946A (zh) * | 2020-05-09 | 2020-09-04 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 分离的新型冠状病毒单克隆抗体或其抗原结合部分 |
WO2021228135A1 (zh) * | 2020-05-13 | 2021-11-18 | 北京大学 | 制备抗原结合单元的方法 |
WO2021244601A1 (zh) * | 2020-06-04 | 2021-12-09 | 山东博安生物技术股份有限公司 | SARS-CoV-2病毒的中和抗体及其应用 |
CN111718411A (zh) * | 2020-06-19 | 2020-09-29 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1F2 |
CN111690059A (zh) * | 2020-06-19 | 2020-09-22 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1D7 |
CN111718411B (zh) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1F2 |
CN111690059B (zh) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的单克隆抗体1D7 |
CN112500481B (zh) * | 2020-11-29 | 2021-08-20 | 山西省人民医院 | 一种人源抗新型冠状病毒的中和活性单克隆抗体 |
CN112500481A (zh) * | 2020-11-29 | 2021-03-16 | 山西省人民医院 | 一种人源抗新型冠状病毒的中和活性单克隆抗体 |
CN113912708A (zh) * | 2021-09-01 | 2022-01-11 | 中国人民解放军军事科学院军事医学研究院 | 单域重链抗体及其编码基因和制备方法及应用和药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN109666070B (zh) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109666070B (zh) | 单克隆抗体mers-4v2及其编码基因和应用 | |
TWI825834B (zh) | 基於艾日布林之抗體-藥物結合物及使用方法 | |
KR102165120B1 (ko) | 인간 면역결핍 바이러스 중화 항체 | |
CN111366735B (zh) | 新型冠状病毒更早期筛查方法 | |
KR102096224B1 (ko) | 폴리펩티드 구축물 및 이의 용도 | |
KR20220167273A (ko) | 항-코로나바이러스 항체 및 사용 방법 | |
AU2015302959B2 (en) | Anti-CDH6 antibody drug conjugates | |
KR20170091179A (ko) | Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법 | |
KR20170005166A (ko) | 인터류킨-1 알파 항체 및 그의 사용 방법 | |
TW201245228A (en) | Fusion proteins for HIV therapy | |
CN113388029B (zh) | 针对新型冠状病毒的中和性人源单克隆抗体及其应用 | |
KR20170089010A (ko) | Bmp6을 표적화하는 항체에 대한 조성물 및 방법 | |
CN112851824A (zh) | 一种融合蛋白及其在制备新型冠状病毒亚单位疫苗中的应用 | |
KR20160021849A (ko) | 렉틴-유사 산화된 ldl 수용체1 항체 및 사용 방법 | |
CN113493506A (zh) | 新型冠状病毒抗体及其应用 | |
CN108277234A (zh) | 封闭cd47并激发抗肿瘤免疫的重组溶瘤腺病毒及其用途 | |
CN108727490B (zh) | 一种单克隆抗体zk2b10及应用 | |
CA3001231A1 (en) | Antibody against hepatitis b surface antigen and use thereof | |
CN107949575B (zh) | Cys80缀合型免疫球蛋白 | |
KR20230142482A (ko) | 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도 | |
HUT70461A (en) | Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv invention | |
CN111434685B (zh) | 抗h7n9全人源单克隆抗体9i17及其制备方法与应用 | |
EP3801766A1 (en) | Hepatitis b antibodies | |
CN111499735B (zh) | 一种针对hiv的双特异性抗体及其编码基因和应用 | |
CN113698487A (zh) | 抗人ace2单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |